What PCPs and geriatricians need to know about robotic prostatectomy and organ-confined prostate cancer.
Prostate cancer is the most common visceral neoplasm diagnosed in the United States and has gained significant public awareness over the past 20 years as a result of the serum prostate-specific antigen (PSA) screening test. Though there is potentially wide variability in presentation, most patients are diagnosed with organ-confined disease. Treatments for localized prostate cancer include surgery, radiation, and active surveillance. One of the newer surgical modalities is robotic-assisted laparoscopic prostatectomy, which has shown promise in improving cancer control and reducing the morbidity commonly associated with open radical prostatectomy. This article will discuss screening and treatment options for localized prostate cancer, with special focus on robotic prostatectomy and its advantages.
Carlucci
John R
JR
Division of Robotics and Minimally Invasive Surgery, Mount Sinai School of Medicine, New York City, NY, USA.
Nabizada-Pace
Fatima
F
Samadi
David B
DB
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001918:Brachytherapy; D055088:Early Detection of Cancer; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D005853:Geriatrics; D006801:Humans; D010535:Laparoscopy; D008297:Male; D008403:Mass Screening; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000295:instrumentation* / Q000379:methods; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000601:surgery* / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D012371:Robotics; D016896:Treatment Outcome
D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen